No Excess Bleeding Risk with Dabigatran

AHA 2012 — LOS ANGELES — Patients starting dabigatran (Pradaxa) did not have a higher risk of bleeding compared with new users of warfarin, according to a post-marketing data review by the FDA.

Keywords: AHA Annual Scientific Sessions


< Back to Listings